Number of (possibly repeated) events and rates thereof in different treatment periods
| Treatment . | . | Patients, n . | Age, y . | Time . | Arterial event, n (rate) . | HR (95% CI) . | P value . | VTE, n (rate) . | HR (95% CI) . | P value . | Major bleeding, n (rate) . | HR (95% CI) . | P value . | All-cause mortality, n (rate) . | HR (95% CI) . | P value . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All time | MF | 1079 | 70.3 | 48.3 | 125 (2.59) | 1.73 (1.40-2.12) | <.001 | 51 (1.06) | 2.75 (1.95-3.90) | <.001 | 123 (2.55) | 3.78 (2.98-4.79) | <.001 | 532 (11.01) | 3.92 (3.50-4.40) | <.001 |
| Controls | 5395 | 69.4 | 223.8 | 337 (1.51) | 86 (0.38) | 152 (0.68) | 630 (2.81) | |||||||||
| No symptom-directed treatment | MF | 720 | 67.6 | 17.7 | 38 (2.15) | 1.49 (1.04-2.15) | .031 | 16 (0.79) | 2.85 (1.53-5.31) | <.001 | 41 (2.32) | 3.31 (2.22-4.94) | <.001 | 209 (11.81) | 4.31 (3.57-5.20) | <.001 |
| Controls | 3517 | 66.6 | 82.2 | 119 (1.45) | 26 (0.32) | 58 (0.71) | 227 (2.76) | |||||||||
| HU | MF | 672 | 73.9 | 20.4 | 48 (2.35) | 1.47 (1.06-2.03) | .020 | 26 (1.27) | 3.17 (1.92-5.21) | <.001 | 42 (2.05) | 3.14 (2.12-4.64) | <.001 | 204 (10.00) | 3.29 (2.75-3.95) | <.001 |
| Controls | 3319 | 73.1 | 93.9 | 150 (1.59) | 38 (0.40) | 62 (0.66) | 283 (3.01) | |||||||||
| IFN | MF | 82 | 55.7 | 2.7 | 1 (0.37) | 0.54 (0.069-4.30) | .56 | 1 (0.37) | 1.66 (0.17-15.98) | .66 | 3 (1.11) | 14.97 (1.56-143.95) | .019 | 6 (2.22) | 3.68 (1.28-10.61) | .016 |
| Controls | 408 | 55.5 | 13.4 | 9 (0.67) | 3 (0.77) | 1 | 8 (0.77) | |||||||||
| JAKis | MF | 238 | 69.5 | 4.5 | 21 (4.67) | 3.59 (2.03-6.35) | <.001 | 7 (1.56) | 4.10 (1.49-11.31) | .0064 | 24 (5.33) | 8.08 (4.18-15.63) | <.001 | 66 (14.67) | 5.81 (4.05-8.34) | <.001 |
| Controls | 1134 | 68.7 | 20.9 | 27 (1.29) | 8 (0.38) | 14 (0.67) | 53 (2.54) | |||||||||
| IMiDs | MF | 55 | 72.3 | 0.46 | 1 (2.17) | 1.15 (0.13-10.29) | .90 | 0 | - | - | 2 (4.35) | 3.22 (0.54-19.27) | .20 | 19 (41.30) | 23.26 (7.91-68.38) | <.001 |
| Controls | 270 | 72.3 | 2.2 | 4 (1.82) | 2 (0.89) | 3 (1.36) | 4 (1.82) | |||||||||
| ESAs | MF | 308 | 74.7 | 4.8 | 15 (3.13) | 1.75 (0.96-3.17) | .066 | 4 (0.84) | 1.01 (0.34-3.00) | .99 | 18 (3.75) | 4.85 (2.50-9.41) | <.001 | 92 (19.17) | 5.25 (3.89-7.08) | <.001 |
| Controls | 1501 | 74.0 | 21.7 | 39 (1.80) | 17 (0.78) | 17 (0.78) | 80 (3.69) | |||||||||
| No antithrombotic treatment | MF | 1019 | 67.4 | 20.1 | 41 (2.04) | 1.66 (1.16-2.37) | .0053 | 19 (0.94) | 2.50 (1.43-4.36) | .0012 | 64 (3.18) | 5.06 (3.56-7.20) | <.001 | 296 (14.73) | 6.33 (5.32-7.53) | <.001 |
| Controls | 5056 | 66.7 | 95.1 | 117 (1.23) | 36 (0.38) | 60 (0.63) | 222 (2.33) | |||||||||
| Antiplatelet agents | MF | 757 | 71.9 | 22.1 | 56 (2.53) | 1.63 (1.20-2.21) | .0017 | 14 (0.63) | 1.76 (0.95-3.27) | .072 | 37 (1.67) | 2.60 (1.74-3.88) | <.001 | 144 (6.51) | 2.14 (1.75-2.61) | <.001 |
| Controls | 3760 | 71.0 | 101.4 | 159 (1.57) | 36 (0.36) | 66 (0.65) | 308 (3.04) | |||||||||
| DOACs | MF | 176 | 75.6 | 3.0 | 12 (4.00) | 1.83 (0.93-3.58) | .080 | 13 (4.33) | 5.83 (2.55-13.30) | <.001 | 11 (3.67) | 4.02 (1.77-9.12) | <.001 | 45 (15.00) | 4.37 (2.89-6.61) | <.001 |
| Controls | 812 | 74.5 | 13.3 | 29 (2.18) | 10 (0.75) | 12 (0.90) | 45 (3.38) | |||||||||
| Warfarin | MF | 115 | 72.5 | 3.0 | 16 (5.33) | 2.29 (1.25-4.19) | .0070 | 6 (2.00) | 3.02 (1.07-8.48) | .036 | 8 (2.67) | 3.00 (1.23-7.34) | .016 | 42 (14.00) | 3.43 (2.29-5.12) | <.001 |
| Controls | 561 | 71.5 | 13.4 | 31 (2.31) | 9 (0.67) | 12 (0.89) | 55 (4.10) | |||||||||
| LMWH | MF | 201 | 66.9 | 1.4 | 10 (7.14) | 4.64 (1.93-11.16) | <.001 | 13 (9.29) | 60.52 (7.91-462.80) | <.001 | 10 (7.14) | 12.10 (3.80-38.59) | <.001 | 24 (17.14) | 7.58 (3.98-14.46) | <.001 |
| Controls | 965 | 66.1 | 6.4 | 10 (1.56) | 1 (0.16) | 4 (0.63) | 15 (2.34) |
| Treatment . | . | Patients, n . | Age, y . | Time . | Arterial event, n (rate) . | HR (95% CI) . | P value . | VTE, n (rate) . | HR (95% CI) . | P value . | Major bleeding, n (rate) . | HR (95% CI) . | P value . | All-cause mortality, n (rate) . | HR (95% CI) . | P value . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All time | MF | 1079 | 70.3 | 48.3 | 125 (2.59) | 1.73 (1.40-2.12) | <.001 | 51 (1.06) | 2.75 (1.95-3.90) | <.001 | 123 (2.55) | 3.78 (2.98-4.79) | <.001 | 532 (11.01) | 3.92 (3.50-4.40) | <.001 |
| Controls | 5395 | 69.4 | 223.8 | 337 (1.51) | 86 (0.38) | 152 (0.68) | 630 (2.81) | |||||||||
| No symptom-directed treatment | MF | 720 | 67.6 | 17.7 | 38 (2.15) | 1.49 (1.04-2.15) | .031 | 16 (0.79) | 2.85 (1.53-5.31) | <.001 | 41 (2.32) | 3.31 (2.22-4.94) | <.001 | 209 (11.81) | 4.31 (3.57-5.20) | <.001 |
| Controls | 3517 | 66.6 | 82.2 | 119 (1.45) | 26 (0.32) | 58 (0.71) | 227 (2.76) | |||||||||
| HU | MF | 672 | 73.9 | 20.4 | 48 (2.35) | 1.47 (1.06-2.03) | .020 | 26 (1.27) | 3.17 (1.92-5.21) | <.001 | 42 (2.05) | 3.14 (2.12-4.64) | <.001 | 204 (10.00) | 3.29 (2.75-3.95) | <.001 |
| Controls | 3319 | 73.1 | 93.9 | 150 (1.59) | 38 (0.40) | 62 (0.66) | 283 (3.01) | |||||||||
| IFN | MF | 82 | 55.7 | 2.7 | 1 (0.37) | 0.54 (0.069-4.30) | .56 | 1 (0.37) | 1.66 (0.17-15.98) | .66 | 3 (1.11) | 14.97 (1.56-143.95) | .019 | 6 (2.22) | 3.68 (1.28-10.61) | .016 |
| Controls | 408 | 55.5 | 13.4 | 9 (0.67) | 3 (0.77) | 1 | 8 (0.77) | |||||||||
| JAKis | MF | 238 | 69.5 | 4.5 | 21 (4.67) | 3.59 (2.03-6.35) | <.001 | 7 (1.56) | 4.10 (1.49-11.31) | .0064 | 24 (5.33) | 8.08 (4.18-15.63) | <.001 | 66 (14.67) | 5.81 (4.05-8.34) | <.001 |
| Controls | 1134 | 68.7 | 20.9 | 27 (1.29) | 8 (0.38) | 14 (0.67) | 53 (2.54) | |||||||||
| IMiDs | MF | 55 | 72.3 | 0.46 | 1 (2.17) | 1.15 (0.13-10.29) | .90 | 0 | - | - | 2 (4.35) | 3.22 (0.54-19.27) | .20 | 19 (41.30) | 23.26 (7.91-68.38) | <.001 |
| Controls | 270 | 72.3 | 2.2 | 4 (1.82) | 2 (0.89) | 3 (1.36) | 4 (1.82) | |||||||||
| ESAs | MF | 308 | 74.7 | 4.8 | 15 (3.13) | 1.75 (0.96-3.17) | .066 | 4 (0.84) | 1.01 (0.34-3.00) | .99 | 18 (3.75) | 4.85 (2.50-9.41) | <.001 | 92 (19.17) | 5.25 (3.89-7.08) | <.001 |
| Controls | 1501 | 74.0 | 21.7 | 39 (1.80) | 17 (0.78) | 17 (0.78) | 80 (3.69) | |||||||||
| No antithrombotic treatment | MF | 1019 | 67.4 | 20.1 | 41 (2.04) | 1.66 (1.16-2.37) | .0053 | 19 (0.94) | 2.50 (1.43-4.36) | .0012 | 64 (3.18) | 5.06 (3.56-7.20) | <.001 | 296 (14.73) | 6.33 (5.32-7.53) | <.001 |
| Controls | 5056 | 66.7 | 95.1 | 117 (1.23) | 36 (0.38) | 60 (0.63) | 222 (2.33) | |||||||||
| Antiplatelet agents | MF | 757 | 71.9 | 22.1 | 56 (2.53) | 1.63 (1.20-2.21) | .0017 | 14 (0.63) | 1.76 (0.95-3.27) | .072 | 37 (1.67) | 2.60 (1.74-3.88) | <.001 | 144 (6.51) | 2.14 (1.75-2.61) | <.001 |
| Controls | 3760 | 71.0 | 101.4 | 159 (1.57) | 36 (0.36) | 66 (0.65) | 308 (3.04) | |||||||||
| DOACs | MF | 176 | 75.6 | 3.0 | 12 (4.00) | 1.83 (0.93-3.58) | .080 | 13 (4.33) | 5.83 (2.55-13.30) | <.001 | 11 (3.67) | 4.02 (1.77-9.12) | <.001 | 45 (15.00) | 4.37 (2.89-6.61) | <.001 |
| Controls | 812 | 74.5 | 13.3 | 29 (2.18) | 10 (0.75) | 12 (0.90) | 45 (3.38) | |||||||||
| Warfarin | MF | 115 | 72.5 | 3.0 | 16 (5.33) | 2.29 (1.25-4.19) | .0070 | 6 (2.00) | 3.02 (1.07-8.48) | .036 | 8 (2.67) | 3.00 (1.23-7.34) | .016 | 42 (14.00) | 3.43 (2.29-5.12) | <.001 |
| Controls | 561 | 71.5 | 13.4 | 31 (2.31) | 9 (0.67) | 12 (0.89) | 55 (4.10) | |||||||||
| LMWH | MF | 201 | 66.9 | 1.4 | 10 (7.14) | 4.64 (1.93-11.16) | <.001 | 13 (9.29) | 60.52 (7.91-462.80) | <.001 | 10 (7.14) | 12.10 (3.80-38.59) | <.001 | 24 (17.14) | 7.58 (3.98-14.46) | <.001 |
| Controls | 965 | 66.1 | 6.4 | 10 (1.56) | 1 (0.16) | 4 (0.63) | 15 (2.34) |
Bold P values are those of statistical significance. Treatment periods are defined from the registry and pharma data for the case group, but each control gets the same period put in for comparison. Treatment periods are not exclusive, for example, the time on one therapy can overlap another treatment. Time is measured in 100-year units.
DOACs, direct oral anticoagulants; ESAs, erythropoietin-stimulating agents; VTE, venous thromboembolism.